Skip to content

China ALK-Positive NSCLC 'Clinical Cure' White Paper

China ALK-Positive NSCLC 'Clinical Cure' White Paper

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122084
Enrollment
Unknown
Registered
2026-04-08
Start date
2026-04-08
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Observation group (190 doctors
150 patients):None

Sponsors

Shanghai East Hospital (Tongji University Affiliated East Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Doctor Inclusion Criteria (1) The department must be Oncology, Respiratory, or Thoracic Surgery; (2) Must have at least 2 years of experience in managing patients with advanced NSCLC; (3) Professional title must be Attending Physician, Associate Chief Physician, or Chief Physician; (4) In the past 6 months, must have experience treating 5 or more ALK-positive non-small cell lung cancer patients. Patient Inclusion Criteria (1) All patients must be ALK-positive NSCLC patients; (2) Must have basic reading comprehension skills, and 20%-30% of patients need to have experience using Lorlatinib.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
Current status of ALK-positive NSCLC management;Physicians' and patients' understanding and acceptance of the concept of "clinical cure";

Countries

China

Contacts

Public ContactZhou Caicun

Shanghai East Hospital (Tongji University Affiliated East Hospital)

caicunzhoudr@163.com+86 133 0182 5532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026